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Approaches and challenges to refining and reducing animal use in regulatory testing are reviewed. 
Regulatory testing accounts for the majority of animals reported in the most painful and/or distressful 
categories in the United States and Canada. Refinements in testing, including the use of humane 
endpoints, are of increasing concern. Traditional approaches to reduction (e.g., improving experimental 
design) are being supplemented with complementary approaches, such as the use of tier testing to 
eliminate some chemicals prior to in vivo testing. Technological advances in telemetry and noninvasive 
techniques will help decrease either the demand for animals in testing or animal suffering. Further 
decreases in animal use will stem from international harmonization and coordination of testing programs. 
Progress in refinement and reduction faces a variety of broad challenges, including limited funding for 
research. In the specific area of refinement, a key challenge is the issue of distress (as distinct from pain). 
In the area of reduction, the practice of using unjustifiably high numbers of animals from small species 
(e.g., rodents) should be challenged. One case study of the use of carbon dioxide as a euthanasia agent 
illustrates the need for further analysis and research. Notwithstanding the complexities and challenges, 




Russell and Burch (1959) proposed the framework of the 3Rs of refinement, reduction, and replacement 
more than 40 yr ago. Since that landmark publication, significant progress has been made, especially in 
the arena of regulatory testing (Stephens et al. 2001). Several reviews of refinement and reduction 
alternatives have been written in recent years (e.g., Festing 1999; Morton 1995, 1998; Rowan 1995). The 
present review concentrates on regulatory testing and focuses primarily on refinement. 
 
We first assess animal use patterns in regulatory testing and the associated levels of animal pain and 
distress experienced in this testing to provide a better sense of use patterns, historical trends, and how 
best to deploy our resources. Perhaps the most comprehensive national statistics come from Great 
Britain. Of the 2.7 million animals used there in 1998, 21% were used in toxicity testing (Home Office 
1999). The types of toxicity studies that account for the bulk of this testing include acute/subacute lethal 
studies (124,000 animals); acute/subacute range-finding, limit testing, and related studies (109,000); and 
reproductive/ teratogen/mutagen studies (71,400). 
 
Data from the United States (Stephens et al. 1998) and Canada (CCAC 1998a) indicate that testing 
procedures account for the vast majority of the animals reported in the highest categories of pain and 
distress. These findings underscore the importance of refining and reducing animal use in regulatory 
toxicity testing. 
 
Approaches to Refinement 
 
Refinements are modifications in animal-based procedures that either decrease pain, distress, and 
discomfort or increase animal well-being (Morton 1995). They can be applied to all aspects of animal care 
and use in the laboratory and can improve scientific outcomes as well as animal welfare (Smaje et al. 
1998). Some key approaches to refinement, summarized below, include humane endpoints, pain and 




Humane endpoints are refinements that allow a study to be ended early, without compromising the 
experiment’s objective or results, thereby precluding any further animal pain and distress. For example, 
Cussler and colleagues (1999) demonstrated that circling behavior in mice reliably predicts death in the 
rabies vaccine challenge test. Consequently, the onset of this sign can be used as a humane endpoint in 
lieu of death. Both the Canadian Council on Animal Care (CCAC 1998b) and the Organization for 
Economic Cooperation and Development (OECD 2000) have recently issued guidelines on humane 
endpoints. ILAR Journal recently devoted an entire issue to the subject (ILAR 2000; also available online 
at <www.nationalacademies.org/ilarjournal>), and the proceedings of a 1998 conference on the subject 
have been published (Hendriksen and Morton 1999). 
 
Pain and Distress Relief 
 
An obvious approach to refining a protocol that would otherwise cause pain or distress is to provide pain- 
or distress-relieving drugs such as anesthetics, analgesics, tranquilizers, and sedatives to preclude or 
alleviate these adverse effects. Although this approach is routine in procedures involving surgery, it may 
also be indicated in other protocols. Administration of test substances through gavage is a common 
procedure in regulatory testing. Murphy and colleagues (2001) found that brief halothane treatment 
before daily gavage administration of vehicle reduced stress-induced weight loss in rats. However, 
anesthetization was associated with incomplete vehicle retention. More troubling, the authors found a 
significant level of gavagerelated deaths, which anesthesia seemed to dramatically reduce (5 of 9 
nonanesthetized animals died or required euthanasia vs. 1 of 37 anesthetized animals). Subacute or 
chronic toxicity studies using gavage could not be carried out if gavagerelated mortality were this high. It 





Another target of refinement in regulatory testing is dose volume. Excessive doses can cause distress. 





A better understanding of the mechanism of a disease process can sometimes enable scientists to modify 
or completely redesign an animal-based test procedure. For example, the traditional test for identifying 
substances that cause allergic contact dermatitis (ACD1) is the guinea pig maximization test, in which 
subjects are exposed to a substance and then monitored for adverse reactions-in this case, the clinical 
signs of ACD (e.g., redness, swelling, blistering). By contrast, the newer, mechanism-based test, the 
murine local lymph node assay, capitalizes on the finding that sensitizers induce proliferation of 
lymphocytes in the lymph node draining the site of chemical application (Kimber and Weisenberger 
1989). Under appropriate test conditions, this lymphocyte proliferation is proportional to the applied dose 
and provides a means of obtaining an objective, quantitative measurement of sensitization. The mice in 
the murine local lymph node assay are euthanized before they show any clinical signs of ACD. 
 
Other Refinement Approaches 
 
There are many other approaches to refinement in regulatory testing and other animal-based procedures. 
These approaches include, but are not limited to, training personnel in best practices; ensuring adequate 
levels of staffing and monitoring; housing animals in nonbarrenS, even enriched, enclosures; using 
indwelling catheters and tethers or osmotic pumps in lieu of repeated injections; acclimatizing animals to 
testing apparatus or training them (particularly primates) to cooperate in chemical administration; and 
housing animals in groups (e.g., Healing and Smith 2000). 
 
Approaches to Reduction 
 
Reduction alternatives are methods that use fewer animals than the conventional procedures but still 
yield comparable levels of information, or methods that use the same number of animals but yield more 
information, so that ultimately, fewer animals are needed to complete a given project or test (Balls et al. 
1995). Reduction alternatives are typically viewed as modifications of existing procedures. For purposes 
of this review, we adopt a broader view to encompass any changes in practice that result in fewer animals 
being used, without compromising test results. Some of the main approaches to reducing animal use in 
regulatory testing are summarized below. 
 
Improving Experimental Design 
 
Festing (1994) has discussed numerous ways to design experiments that use fewer animals while 
yielding equivalent or greater statistical power. For example, sequential designs often use substantially 
fewer animals than dosing all animals at the start of a procedure. This approach has been successfully 
applied to acute toxicity testing, with the fixed dose procedure, acute toxic class method, and the up-and-
down method, each of which uses fewer animals than the conventional LD50 test (Festing et al. 1998). 
Using the limit test is another way to reduce animal use in acute toxicity studies. 
 
Using Genetically Defined Animals 
 
Russell and Burch (1959) and Festing (1999) have championed the use of animals with genetically 
defined back grounds as a way of limiting statistical variance and thereby reducing the number of animals 
needed to achieve a given level of discriminatory power. This approach includes use of in-bred strains as 
well as crosses of two in-bred strains. 
 
 
Using Screens in Tiered Testing 
 
Using nonanimal screening procedures in a tiered testing scheme can eliminate some chemicals from 
further testing in higher tiers, thereby reducing animal use. This approach has been applied to several 
areas, including eye irritancy (with pH determination precluding some Draize testing) and carcinogenicity 
(with a positive Ames test substituting for 2-yr rodent bioassays). Prescreens offer promise in the field of 
acute toxicity testing, and cytotoxicity tests are being explored as a means of screening out toxic 
chemicals, in particular (NIEHS 2001 ; Spielmann et al. 1999). Prescreens also offer promise in the field 
of endocrine disruptor testing, where quantitative structure-activity relationships and high throughput 
prescreens are being explored. 
 
Technological Advances Facilitate Refinement and Reduction 
 
A number of technological advances appear promising in the context of reducing or refining animal use in 
regulatory testing. Telemetry is already being applied to the field of drug discovery. However, it does 
entail surgical implantation of a transmitter, and it could be argued that the pain and distress associated 
with this surgery offsets the distress subsequently avoided through remote monitoring. Nevertheless, 
telemetry has the potential to reduce animal numbers dramatically (Kramer et al. 2001). The reduction 
stems from the ability to monitor the same animal over time repeatedly, rather than euthanizing animals at 
various times to assess treatment effects. To date, the application of telemetry to regulatory testing has 
been limited to experimental assessment of specific chemicals, primarily pharmaceutical candidates. 
However, the increasing miniaturization, sophistication, and affordability of telemetry will allow this 
technology to be used more widely in testing. 
 
Similarly, advances in imaging techniques such as magnetic resonance imaging and positron emission 
tomography, like telemetry, allow the same animal to be monitored repeatedly over time, thereby reducing 
animal numbers (Balaban and Hampshire 2001; Cherry and Gambhir 2001; Paulus et al. 2001). 
 
In the future, microarrays of genetic material (e.g., genomics), their products (proteomics), and 
metabolites (metabonomics) may serve as prescreens and, eventually, definitive tests, thereby reducing 
or replacing animal procedures for some testing applications. Similarly, integrated computer modeling 





Regulatory testing is the outcome of policy decisions at national and international levels. These decisions 
have ramifications for the scale of animal use and any resulting pain and distress. In pharmaceutical 
testing, representatives of government and industry in Europe, the United States, and Japan saw the 
need for international harmonization of testing requirements and protocols and established the 
International Conference on Harmonization to meet this challenge. Although the mission of the 
conference was not animal welfare per se, its harmonization efforts have significantly reduced animal use 
in pharmaceutical testing (Osterberg 2001). 
 
Similarly, there is a critical need to coordinate large-scale testing programs being developed at both 
national and international levels, such as efforts to assess endocrine disrupters. The targets for 
coordination include the chemicals and endpoints to be assessed, the protocols to be used, and 
validation of chosen protocols. The Organization for Economic Cooperation and Development has begun 
playing a role in coordinating these programs. 
 
Animal protection organizations are beginning to be recognized as stakeholders in the development of 
testing programs that may involve animal use. Consequently, their voices are now beginning to be heard 
when government agencies formulate these programs, which should help ensure proper consideration 
and integration of the 3Rs. 
 
The evolution of the US high production volume (HPV1) chemical testing program illustrates how 
concerns about the 3Rs and animal welfare, raised by animal protection organizations and the 
alternatives community, can reduce the scale of animal use in a developing program and promote the 
development of alternative methods, all without compromising the goals of the program. The US 
Environmental Protection Agency (EPA1) initially developed the HPV program without seeking any input 
from animal protection stakeholders. After the program was publicly announced in 1998, animal 
protectionists voiced their concerns to EPA, Congress, and other decision makers. The Center for 
Alternatives to Animal Testing (Johns Hopkins University, Baltimore, Maryland) held a series of 
workshops on how the 3Rs could be applied. This attention culminated in an agreement in which the EPA 
pledged to make several changes in the HPV program that would lead to a substantial reduction in animal 
use. The government also agreed to spend $4.5 million on the development of relevant nonanimal 
methods. 
 




There are several broad challenges to the development and implementation of refinement and reduction 
alternatives that should be addressed to expedite progress in advancing humane experimental technique. 
These challenges include the following: 
 
 Encouraging greater funding of alternatives research 
 
We see funding as the major driver of innovation in the 3Rs. Consequently, the current, limited 
level of such funding is a major impediment to progress (see 
<http://altweb.jhsph.edu/databases/funding/funding.htm> for a country-by-country list of available 
sources of alternatives funding). Modest levels of funding can go a long way in refinement and 
reduction research, in that expensive, large-scale validation exercises are usually not needed. 
Those seeking to persuade funding institutions, including governments, to support alternatives 
research should emphasize the resulting benefits to science as well as animal welfare. 
 
 Better ways to translate best practices into standard practices 
 
It is not enough simply to develop new refinement and reduction alternatives; these techniques 
must be incorporated into practice. Regulatory requirements to consider alternative methods can 
help foster the implementation of new techniques. However, an important prerequisite of progress 
is to publish or otherwise disseminate innovations. Professional societies should encourage the 
publication of new alternative techniques relevant to their disciplines, and, when appropriate, 
regulatory agencies should bring significant developments in alternative methods to the attention 
of regulated parties, as was the case with monoclonal antibody production in the United States 
(see <http://altweb.jhsph.edu/publications/misc/oprr.htm>). 
 
 Developing new testing programs that incorporate refinement, reduction, and replacement 
alternatives into regulators’ programs to the fullest extent possible, and to avoid any bias in 
assessing the applicability of in vitro versus in vivo methods 
 
Technical experts should work with more politically oriented proalternative organizations to 
ensure that regulatory agencies give proper consideration to existing alternative methods. 
Moreover, agencies attempting to launch large-scale animal testing programs should devote 
substantial funding to research and development of alternative methods, so that such methods 
can be incorporated into the programs. 
 
 Harmonizing national statistics on animal use patterns so that rational priorities for reduction and 
refinement research can be identified internationally 
 
Given the limited funding currently available for alternatives research, priorities for this research 
should be set based on pertinent considerations such as the number of animals used in a given 
procedure annually and the level of pain and distress entailed in the procedure. This information 
can sometimes be gleaned from national statistics on animal use, but it would be even more 
helpful if harmonized international figures were available. The European Union has begun issuing 
periodic reports on the number of research animals used by member states (the latest report is 
available at <http://europa.en.int/comm/environment/documen/99191_en.htm>). This first step 
toward a more global effort is promising. 
 
Specific Challenges: Refinement and Reduction 
 
In addition to the more general challenges identified above, several more specific impediments to 
progress in refinement and reduction can be identified. In these areas, we believe the following 
challenges are among the most important: 
 
 Better understanding of distress, especially non-pain-induced distress and discomfort, and how to 
identify, quantify, and prevent or alleviate it (Rowan et al. 1998) 
 
Considerably more attention has been paid to pain than to distress, and we believe this 
imbalance has led to an underappreciation of the incidence and severity of distress, as well as to 
the adverse impact of any distress on the scientific results and conclusions. 
 
 More reliable indicators of adverse effects to determine the relative roles of indices (e.g., weight 
loss, body condition, behavior, and hormone levels) and how multiple indicators can be combined 
into an integrated approach, as in the use of score sheets (e.g., Morton 2000) 
 
Good assessment measures are critical to evaluating potential refinements (Flecknell 1994). 
 
 Development of endpoints well before the moribund state 
 
As a result of the call for more humane endpoints, death as an endpoint is increasingly 
questioned. The most common endpoint substituting for death is the moribund condition. 
Although the motives are good, an animal that reaches the moribund state probably experiences 
as much distress as one that dies. 
 
 Discrimination on the basis of body size without adequate justifification 
 
When a choice between species is possible, the practice of using higher numbers of animals 
simply because they are smaller (or less expensive) should be challenged (Balls et al. 1995). 
 
 Animal waste from single-sex testing requirements 
 
Mismatches between supply and demand create surpluses of one sex or the other that result in 
euthanizing unwanted animals (Festing et al. 1998). 
 
 An array of often-overlooked variables 
 
Variables such as circadian rhythms and repeated handling not only can compromise 
experimental results in pharmacology and neuroscience research but also can lead to 
unnecessarily high levels of animal use or pain and distress (Claassen 1994). The proper control 
of these variables will not only improve the quality of ex perimental results but can also refine or 
reduce animal use. 
 
Case Study: Carbon Dioxide as a Euthanasia Agent 
 
One of the key approaches to challenging the status quo in animal use is to conduct detailed 
assessments of common animal-based techniques to determine whether these techniques are 
candidates for refinement, reduction, or replacement. The Humane Society of the United States has 
conducted such a review of the use of carbon dioxide as a euthanasia agent (see 
<http://www.hsus.org/ace/11427>). Our analysis of published data raises several concerns about the 
routine use of carbon dioxide, which include the following: 
 
1. The evidence on whether C02 causes pain and distress in animals is mixed. Some C02 studies 
report no pain or distress (e.g., Hewett et al. 1993); others report the opposite (e.g., Coenen et al. 
1995). 
 
2. C02 has been used in human and rodent studies as a pain- and stress-inducing stimulus (e.g., 
Anton et al. 1992), which suggests that C02 is indeed painful or stressful to animals, at least 
under certain conditions. 
 
3. Adverse reactions, including seizure, nose hemorrhage, rearing, defecation, and excessive 
salivation, have been noted in rodents and other species at C02 concentrations of >50% (e.g., 
Ambrose et al. 2000). 
 
4. Histological analyses of animals reveal lung edema and hemorrhage at all concentrations of C02 
use (e.g., Fawell et al. 1972). 
 
5. The literature is mixed as to which of two common methods of C02 induction (prefilling the 
chamber vs. gradual induction) is preferred. Distress has been reported with each method. 
 
6. The shortest time to collapse reported at the 70% C0 2concentration recommended by the 
American Veterinary Medical Association is approximately 10 sec (Mischler et al. 1994) although 
one study reported that anesthesia did not occur until 4.01 min (Danneman et al. 1997). This 
duration allows for a significant amount of time for the animal to suffer before becoming 
unconscious. 
 
7. Humans experience pain when the C02 concentration is 50% and higher (e.g., Danneman et al. 
1997). US Government Principle #4 and US Department of Agriculture Policy #11 both state that 
procedures causing pain and distress in humans should be assumed to cause pain and distress 
in animals, absent “evidence to the contrary” (US Government Principle #4; PHS 1993). In the 
case of C02, the animal data are equivocal but the human data are clear. Therefore, The 
Humane Society of the United States argues that the continued use of C02 as a euthanasia agent 
is inconsistent with government principle #4 and US Department of Agriculture policy #11. 
 
A number of organizations, including the American Veterinary Medical Association (AVMA 2001), the 
Canadian Council on Animal Care (1993), the European Commission (1996), and the Australian and New 
Zealand Council for the Care of Animals in Research and Teaching (Reilly 1993), currently support the 
use of C02 for euthanasia of rodents and provide guidelines on its use. These guidelines differ in 
significant ways. In summary, the evidence of potential pain and distress associated with the use of 
carbon dioxide as a sole agent for euthanasia indicates that its routine use for this purpose should, at the 
very least, be questioned. Consequently, refinements to the use of C02 as a sole agent for euthanasia, 
such as the use of an inhalation anesthetic before exposing animals to C02, should be considered. 




Reduction and refinement alternatives have significant potential to decrease the use and suffering of 
animals used in regulatory testing further. The pace of future progress in these areas will depend on how 




1Abbreviations used in this presentation: ACD, allergic contact dermatitis; EPA, US Environmental 
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